Background Pathogen inactivation methods for platelet concentrates are increasingly being used in blood banks worldwide. In vitro studies have demonstrated its effects on storage lesion, but little routine quality control data on blood banking outcomes have been reported.
Introduction
The impact of (Intercept) pathogen inactivation on platelets has been studied extensively in experimental conditions, but quality control data from routine use are less common. Experimental research has demonstrated that quality control parameters [1] of Intercept pathogen-inactivated platelets generally are within predefined ranges [2] [3] [4] but with a significant impact on in vitro function [5] . This is caused by irreversible changes in the platelet plasma membrane which affect subsequent intracellular signal transduction [6] . Clinical studies have demonstrated significantly lower corrected count increments at 1 and 24 h, shorter transfusion intervals and increased transfusions of Intercept-treated platelets compared to standard concentrates [7, 8] . However, no differences in mortality, clinically significant bleeding or severe bleeding were found in a meta-analysis of these trials [9] . Of note, the practical impact on blood component processing is significant because several adaptations in the production chain are required to meet acceptance criteria [10] .
Here, we describe the results of our extended QC programme, obtained during the first year of routine pathogen inactivation use. Our quality control routine includes monitoring of pH, glucose and lactic acid on a random subset of expired products as well as monitoring swirling score of every platelet concentrate to be issued. In addition, during the first year of routine pathogen inactivation use, apheresis platelet concentrates with 'premature' low swirling score (i.e. before expiration day) were transferred to the research centre for further analysis and compared to expired day 6 platelet concentrates with normal swirling. This quality control series indicated increased chances of storage lesion following Intercept pathogen inactivation particularly for apheresis platelet concentrates with platelet contents higher than 5Á0 9 10 11 .
Materials and methods

Apheresis platelet concentrate production
Single-donor platelet concentrates were collected by apheresis using the Trima Accel Automated Blood Collection System (Terumo BCT, Lakewood, CO, USA). Final product volumes and platelet content were set to comply with the Intercept pathogen inactivation method guard bands of 'Large Volume' bag sets (Table 1) . Platelet additive solution (SSP+, Macopharma, Tourcoing, France) was added aiming for a fixed plasma carryover of 40% (v/v). In case the donor was eligible for double-dose apheresis, volumes above 610 mL were set, allowing splitting to the compliant volume ranges after collection. These doubledose concentrates were split to two separate 'Large Volume' bag sets prior to Intercept treatment. 'Dual storage' bag sets were used specifically when a paediatric platelet product (1Á6 9 10 11 platelets) was to be derived from the donation. In that case, splitting took place right after Intercept treatment. All apheresis platelet concentrates were stored in the storage containers of the Intercept illumination set.
Buffy coat-derived platelet concentrate production
Concentrates prepared by the buffy coat method were from whole blood donations. Six buffy coats were manually pooled as described [5, 11] , supplemented with SSP+ additive solution and then treated with Intercept pathogen inactivation prior to storage. In this case, a fixed amount of additive solution of 280 ml was added, resulting in a variable plasma content between 33% and 37% (v/v). All buffy coat-derived platelet concentrates were stored in the storage containers of the Intercept illumination set.
Laboratory methods
Standard quality control included determination of pH, glucose and lactic acid levels of a random cohort of expiring buffy coat and apheresis-derived platelet concentrates. Prior to distribution, platelet concentrates were routinely assessed for swirling yielding an integral score between 0 and 3. Products with a low swirling score ≤1 were considered inappropriate for issuing. On the day of assessment, these product numbers were introduced in the electronic tracking system. All products with premature low swirling score were thus counted in the year before (2014) and after (2015) introduction of Intercept pathogen inactivation.
Apheresis platelet concentrates with premature low swirling score were further analysed for platelet count, platelet concentration, mean platelet volume (MPV), pH, lactic acid, glucose and expression of surface receptors by flow cytometry. These laboratory analyses were performed on the day of assessment, thus excluding those flagged during weekends. These concentrates were compared to regularly expiring apheresis products assessed (day 6) with a swirling score ≥2. Platelet counts and MPV were measured on an automated haematology analyser (pocH-100i; Sysmex, Kobe, Japan). Metabolic parameters were measured on a pointof-care blood gas analyser (Siemens RapidPoint 500, Munich, Germany), but pH was assessed separately using a calibrated glass electrode at 21°C. Flow cytometry was performed essentially as described [5] . In brief, expression of P-selectin (anti-CD62P~phycoerythrin, BD Biosciences, Erembodegem, Belgium), activated integrin a IIb b 3 (PAC1~fluorescein, BD Biosciences) and phosphatidylserine (Annexin V~Peridinin chlorophyll-Cy5Á5; BD Biosciences) was determined using an acoustic focusing flow cytometer (Attune, Life Technologies, Carlsbad, CA, USA). Platelets were incubated with labelled antibodies or ligand for 10 min at room temperature in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, pH 7Á4 with 0Á9% (w/v) NaCl (HBS), 1 mM MgSO 4 and 5 mM KCl, then diluted a 1000-fold immediately before readout as described before [12] . For Annexin V measurements, buffers were supplemented with 2 mM CaCl 2 . For measurements of integrin a IIb b 3 activation on stimulated platelets, the PAR1 agonist thrombin-related activating hexapeptide SFLLRN (TRAP, Sigma-Aldrich, St Louis, MO, USA) was added at 30 lM, or cross-linked collagen-related peptide at 5 lg/ml (CRP, University of Cambridge, Cambridge, United Kingdom). The signals of the isotype antibody controls were used to set threshold gates including 0Á5% of 10 000 negative events. For annexin V gating, samples were incubated with annexin V in the absence of ionized calcium. Median fluorescence intensities and percentage positive events were determined of 10 000 cells staining positive for the platelet marker CD61 (anti-CD61~allophycocyanin, Life Technologies).
Statistics
Sample means were compared by t-test or Mann-Whitney for parametric and non-parametric data sets, respectively. Chi-square analysis was used to assess contingency tables. A significance level of 0Á05 was used. Computational analysis was with Prism (GraphPad Software Inc, La Jolla, CA, USA).
Results
Apheresis concentrates with high platelet content show signs of increased storage lesion
Experimental process validation to implement Intercept pathogen inactivation showed that the pH decreased faster in apheresis concentrates compared to pooled buffy coat platelet concentrates (Fig. 1a) . Apheresis units with low platelet content (<1Á7 9 10 11 ) intended for paediatric use did not show this decline suggesting platelet content plays a role as well. Glucose levels on day 6 were moreover lower in the high content apheresis products (Fig. 1b) compared to pooled buffy coat platelet concentrates, despite 3-7% more plasma carryover. All concentrates had normal swirling throughout the study. This was confirmed in routine use because the incidence of glucose levels below detection limit was higher in apheresis (5/20) than in buffy coat-derived (1/75) products (Fig. 2) . The median (range) platelet content of these products was not different (apheresis 3Á7 (3Á4-5Á4) 9 10 11 vs. buffy coat 3Á9 (3Á0-5Á4) 9 10 11 , P = 0Á71). Incidence of low swirling was increased in concentrates prepared by apheresis but not by the buffy coat method
In the first year following implementation of Intercept pathogen inactivation, the number of apheresis products with a low swirling score (≤1) increased by 50% (63/ 12 492) compared to the previous year without pathogen inactivation (42/12 931, P = 0Á030, Chi-square). In contrast, the incidence of low swirling score in platelet concentrates prepared by the buffy coat method decreased (2/ 15 286 vs. 10/13 488, P = 0Á025, Chi-square) (Fig. 3) .
Increased storage lesion in apheresis platelet concentrates with low swirling score
Next, apheresis platelet concentrates with premature low swirling score (n = 28) were compared to regular products expiring on day 5 with normal swirling score (n = 34). All were routine products treated with Intercept pathogen inactivation. Apheresis concentrates with low swirling score contained more platelets and at a higher concentration than regular products (P < 0Á0001, Fig. 4a,b ). These data sets had a skewed distribution towards the upper range for products with low swirling score as shown in the histograms in Fig. 4(c,d) .
Metabolic parameters indicated increased anaerobic metabolism in apheresis concentrates with low swirling because the pH was decreased (P < 0Á0001, Fig. 5a ) and lactic acid concentrations were increased (P = 0Á0002, Fig. 5b ) compared to regular products. None of the products had pH levels below 6Á4. Glucose concentrations were inversely related to lactic acid (Fig. 5c ) and far more products had glucose levels below the detection limit (1Á1 mM) of the blood gas analyser (Fig. 5d ) in the cohort with premature low swirling score.
Other storage lesion parameters like MPV (Fig. 6a) , annexin V binding (Fig. 6b) and P-selectin expression (Fig. 6c) were also significantly different (P < 0Á0001). Platelet integrin a IIb b 3 in products with low swirling score was not prematurely activated ( Fig. 6d , P = 0Á99) but responded less to TRAP and CRP stimulation (Fig. 6e,f) . We moreover found a significant correlation (P < 0Á0001) between anaerobic respiration and the amount of platelets, especially when combining the data from the premature low swirling products and the regular products (Fig. 7) .
Discussion
The implementation of Intercept pathogen inactivation for platelets demands significant changes in the primary production process of platelet concentrates [10] . To decrease complexity, we chose to only use 'Large Volume' bag sets [13] supplemented with a small number of 'Dual Storage' bag sets for paediatric purposes. Because the Belgian competent authority advocated a minimal platelet dose of 3Á0 9 10 11 for pathogen-inactivated concentrates, our primary apheresis and buffy coat production processes were adapted so to not only meet the Intercept guard bands set by the manufacturer but also include the critical lower dose limitation. Overall, this has led to platelet concentrates with a relatively high mean platelet content. The current study shows that platelet content alone does not necessarily relate inversely to quality, at least in the content ranges produced in our facilities and for pooled buffy coat concentrates. Indeed, Intercept pathogen inactivation-treated concentrates prepared from six buffy coats did not show increased incidence of low swirling compared to when pathogen inactivation was not in place. On the other hand, in the year following implementation of pathogen inactivation, a greater proportion of apheresis platelet concentrates with high platelet content had decreased swirling compared to those prepared from buffy coat, although none of these units had pH levels below the 6Á4 threshold.
The initial validation study for implementation of the Intercept pathogen inactivation process indicated that pH and glucose levels would decrease faster for apheresis than for buffy coat concentrates despite comparable platelet content, suggesting that apheresis predisposes to increased storage lesion rates. However, because apheresis units with low platelet content (1Á6 9 10 11 ) did not show this, we reasoned that platelet content must combine with apheresis to generate the effect. In a comparable validation study of Chavarin et al. [14] (n = 16), slightly increased storage lesion rates for apheresis products compared to buffy coat-derived products were also found with product quality measures well within standards.
There are several studies that have reported on the quality of apheresis platelet concentrates treated with Intercept pathogen inactivation [3, [14] [15] [16] [17] . It is important to note that all of these studies have in common that platelet contents were well below 5Á0 9 10 11 (Table 2) which is relevant because this was the median content of apheresis concentrates that presented with premature low swirling. Furthermore, the published longitudinal research studies require regular sampling in the millilitre range which significantly decreases the actual platelet content during storage thereby potentially biasing the realistic influence of content on storage lesion rates. Overall, the current data set suggests that platelet content is relevant in pathogen-inactivated apheresis concentrates especially above 5Á0 9 10 11 .
However, the actual number of apheresis concentrates produced in our blood bank containing more than 5Á0 9 10 11 platelets is estimated to be twenty fivefold higher than the incidence of premature low swirling. This suggests that a noticeable change in swirling indicates end-stage quality loss and cannot be used to monitor ongoing deterioration. Consequently, apheresis concentrates with a high platelet content might have had laboratory signs of increased storage lesion like glucose exhaustion or poor integrin responses but not necessarily poor swirling. This can also be concluded from the initial validation study where platelet concentrates with high content had lowered pH values and glucose levels at day 5 but normal swirling. Therefore, in the context of Intercept pathogen inactivation, it may be instructive to (re) determine apheresis platelet concentrate quality in function of content especially in ranges above 5Á0 9 10 11 and to investigate whether this influences clinical outcomes like CCI. Finally, it is difficult to speculate on the reasons why apheresis but not buffy coat-derived concentrates would be more vulnerable in this particular context and for this outcome (low swirling), especially because differences in typical storage lesion markers between buffy coat-derived and apheresis-derived platelet concentrates are minor [18, 19] . We do think that the actual platelet content in the final (split) apheresis product is of matter and not necessarily the targeted (high dose) one before splitting because double-dose or triple-dose apheresis procedures do not yield products with quickly declining quality, at least when these are split within a couple of hours after donation [20, 21] . In our study, there was no difference between the number of double apheresis donations in the non-swirling group (2/28) versus the normal swirling group (4/26). On the same line, platelet content does not necessarily relate in a linear fashion to pH or storage lesion [22] in ranges below 5Á0 9 10 11 [18, 23] . However, only when larger contents are analysed in a scatter plot like in Fig. 7 do such correlations become apparent [24] .
In conclusion, real-world quality control data have indicated a small but significant increase in apheresis products with premature low swirling following the introduction of Intercept pathogen inactivation. This was not observed in similarly inactivated products prepared by the buffy coat method. Our data suggest that especially apheresis products with a content above 5Á0 9 10 11 are at risk indicating the need for validation in the upper guard band range for Intercept-treated apheresis concentrates. 
